Table 1.
Baseline patient characteristics
| Parameter | N = 27 |
|---|---|
| Age (years), mean (SD) | 49.8 (12.7) |
| Women, n (%) | 14 (51.9) |
| BMI, mean (SD) | 28.4 (5.9) |
| Smoking, n (%) | |
| Non-smoker | 19 (70.4) |
| Former smoker | 8 (29.6) |
| Age at diagnosis (years), mean (SD)a | 30.2 (12.2) |
| Time since diagnosis (years), mean (SD) | 19.2 (13.8) |
| Asthma phenotype, n (%) | |
| Eosinophilic | 24 (88.9) |
| Eosinophilic and atopic | 3 (11.1) |
| Pre-BD FEV1, mean (SD)b | |
| mL | 1,813.3 (480.8) |
| % | 62.1 (14.6) |
| Post-BD FEV1, mean (SD)b | |
| mL | 1,989.3 (819.7) |
| % | 65.7 (20.5) |
| ACTc | |
| Mean (SD) | 14 (6.1) |
| Controlled asthma (ACT ≥ 20), n (%) | 6 (22.2) |
| miniAQLQ, mean (SD) | 3.4 (0.7) |
| FeNO (ppb), Mean (SD)d | 76.2 (56.5) |
| Blood eosinophil count (cells/μL), mean (SD)a | 371.9 (315.5) |
| < 300 cells/μL, n (%) | 11 (40.7) |
| ≥ 300 cells/μL, n (%) | 15 (55.6) |
| Total IgE (IU/ml), mean (SD)b | 593.1 (1,054.5) |
| Asthma-treatment in the previous year, n (%) | |
| ICS + LABA | 27 (100) |
| OCS | 24 (88.9) |
| LAMA | 22 (81.5) |
| LTRA | 17 (63) |
| ICS | 8 (29.6) |
| Macrolides | 6 (22.2) |
| Theophylline | 1 (3.7) |
| LABA | 1 (3.7) |
| Biologic agent | |
| Mepolizumab (anti-IL5) | 23 (85.2) |
| Reslizumab (anti-IL5) | 2 (7.4) |
| Omalizumab (anti-IgE) (first line)/Mepolizumab (second line) | 1 (3.7) |
| Omalizumab (first line)/Reslizumab (second line) | 1 (3.7) |
| Oral prednisone dose (mg/day), mean (SD) | 20.3 (20.1) |
| Inhaled budesonide (in combination) dose (μg/ day), Mean (SD) | 305 (60.2) |
| Duration of prior biologic therapy (days), mean (SD) | |
| Duration of prior mepolizumab therapya | 250.8 (167.6) |
| Duration of prior reslizumab therapy | 150.7 (58.4) |
| Duration of prior omalizumab therapy | 77 (107.5) |
| Time since prior biologic therapy (days), mean (SD)a | 121.4 (110.7) |
ACT Asthma Control Test, AQLQ Asthma Quality of Life Questionnaire, BD bronchodilator, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroids, IL-5 Interleukin 5, IU international units, LABA long acting β2-agonists, LAMA long acting muscarinic antagonists, LTRA leukotriene receptor antagonists, μL microliter, mL millilitre, OCS oral corticosteroids, ppb parts per billion, SD standard deviation, SPT skin prick test
aData unknown in 1 case (3.7%)
bData unknown in 6 cases (22.2%)
cData unknown in 2 cases (7.4%)
dData unknown in 8 cases (29.6%)